国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
20期
2546-2548
,共3页
伍启康%雷兰芳%黄燕婷%谭智毅%杨洁飞%徐晓丽
伍啟康%雷蘭芳%黃燕婷%譚智毅%楊潔飛%徐曉麗
오계강%뢰란방%황연정%담지의%양길비%서효려
胸苷激酶1%乳腺癌%诊断%治疗
胸苷激酶1%乳腺癌%診斷%治療
흉감격매1%유선암%진단%치료
Thymidine kinase 1%Breast cancer%Diagnosis%Treatment
目的 探讨胸苷激酶1(TK1)在乳腺癌诊断和治疗中的应用价值.方法 利用酶免疫点印迹化学发光法分别检测205例乳腺癌患者、150例健康体检者的血清TK1浓度,统计阳性率.结果 乳腺癌患者未经治疗组TK1平均浓度为2.65 pmol/L,其阳性率为67.7%;健康体检者组TK1平均浓度为0.96 pmol/L,其阳性率为12.7%,组间比较,差异有极显著性(P<0.01);乳腺癌患者治疗缓解组TK1平均浓度以及阳性率与预后不良组及未经治疗组比较,差异有极显著性(P<0.01).结论 胸苷激酶1在乳腺癌的辅助诊断和治疗过程中的疗效监测及预后判断具有一定的临床应用价值.
目的 探討胸苷激酶1(TK1)在乳腺癌診斷和治療中的應用價值.方法 利用酶免疫點印跡化學髮光法分彆檢測205例乳腺癌患者、150例健康體檢者的血清TK1濃度,統計暘性率.結果 乳腺癌患者未經治療組TK1平均濃度為2.65 pmol/L,其暘性率為67.7%;健康體檢者組TK1平均濃度為0.96 pmol/L,其暘性率為12.7%,組間比較,差異有極顯著性(P<0.01);乳腺癌患者治療緩解組TK1平均濃度以及暘性率與預後不良組及未經治療組比較,差異有極顯著性(P<0.01).結論 胸苷激酶1在乳腺癌的輔助診斷和治療過程中的療效鑑測及預後判斷具有一定的臨床應用價值.
목적 탐토흉감격매1(TK1)재유선암진단화치료중적응용개치.방법 이용매면역점인적화학발광법분별검측205례유선암환자、150례건강체검자적혈청TK1농도,통계양성솔.결과 유선암환자미경치료조TK1평균농도위2.65 pmol/L,기양성솔위67.7%;건강체검자조TK1평균농도위0.96 pmol/L,기양성솔위12.7%,조간비교,차이유겁현저성(P<0.01);유선암환자치료완해조TK1평균농도이급양성솔여예후불량조급미경치료조비교,차이유겁현저성(P<0.01).결론 흉감격매1재유선암적보조진단화치료과정중적료효감측급예후판단구유일정적림상응용개치.
Objective To explore the application value of thymidine kinase 1(TK1) for breast cancer diagnosis and treatment.Methods Serum TK1 concentration and positive rate were detected respectively in 205 patients with breast cancer and 150 healthy cases control with western blot-enhanced chemiluminecence.Results TK1 average concentration of patients with breast cancer in untreated group was 2.65 pmol/L; and its positive rate was 67.7%.TK 1 average concentration of healthy control group was 0.96 pmol/L; and its positive rate was 12.7%.There was significant difference(P<0.001) among groups.The TK1 average concentration and positive rate had significant difference (P<0.001) among the breast cancer patients in the remission stage of treatment group,the poor prognosis group,and untreated group.Conclusion TK1 has certain value of clinical applications on breast cancer auxiliary diagnosis,curative effect monitoring during treatment,and prognosis estimate.